SCHEMBL21292830

SCHEMBL21292830

CN(C)C(=O)[C@H](N)Cc1c[nH]c2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.70
MAPT P10636 2/20 0.70
MEN1 O00255 2/20 0.70
TSHR P16473 2/20 0.70
KMT2A Q03164 2/20 0.70
LMNA P02545 1/20 0.70
MPO P05164 1/20 0.70
BLM P54132 1/20 0.70
PMP22 Q01453 1/20 0.70
HIF1A Q16665 1/20 0.70
MMP9 P14780 1/20 0.61
MMP8 P22894 1/20 0.61
MMP14 P50281 1/20 0.61
HTR2A P28223 2/20 0.60
ADRB1 P08588 1/20 0.60
HTR1A P08908 1/20 0.60
ADRA2A P08913 1/20 0.60
SLC6A2 P23975 1/20 0.60
HTR1D P28221 1/20 0.60
HTR1B P28222 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4126005 1.00 KDM4E (0.70) KDM4EMAPTMEN1TSHRKMT2A
SCHEMBL2992113 1.00 KDM4E (0.70) KDM4EMAPTMEN1TSHRKMT2A
Trifluoroacetic Acid SCHEMBL2493131 0.92 KDM4E (0.63) KDM4EMAPTMEN1TSHRKMT2A
SCHEMBL26768357 0.87 KDM4E (0.64) KDM4EMAPTMEN1TSHRKMT2A
SCHEMBL21309653 0.86 KDM4E (0.67) KDM4EMAPTMEN1TSHRKMT2A
SCHEMBL7620106 0.86 CDK4 (0.66) KDM4EMAPTMEN1TSHRKMT2A
SCHEMBL8345148 0.85 TACR1 (0.69) KDM4EMAPTMEN1TSHRKMT2A
SCHEMBL8345144 0.85 TACR1 (0.69) KDM4EMAPTMEN1TSHRKMT2A
SCHEMBL8487588 0.85 KDM4E (0.68) KDM4EMAPTMEN1TSHRKMT2A
SCHEMBL30230046 0.85 TACR1 (0.69) KDM4EMAPTMEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3759075-B1 COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE FERRO THERAPEUTICS INC (US) 2025-07-23 EP disclosed
US-20230039846-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2023-02-09 US disclosed
US-20230039846-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2023-02-09 US disclosed
US-20190263802-A1 COMPOUNDS AND METHOD OF USE MOLECULAR SKIN THERAPEUTICS, INC. 2019-08-29 US disclosed
US-20190263802-A1 COMPOUNDS AND METHOD OF USE MOLECULAR SKIN THERAPEUTICS, INC. 2019-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039846-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 KDM4E 2312/4885MAPT 4231/4885MEN1 1772/4885
US-20190263802-A1 COMPOUNDS AND METHOD OF USE AIFM2, GPX4, GPX1 KDM4E 2426/4885MAPT 4042/4885MEN1 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.